A5022036881- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Curcumin's Biomedical Applications
- Nanowire Synthesis and Applications
- Meat and Animal Product Quality
- Immune Response and Inflammation
- Biochemical Analysis and Sensing Techniques
- Immune Cell Function and Interaction
- Bioactive natural compounds
- Calcium signaling and nucleotide metabolism
- Probiotics and Fermented Foods
- Immune cells in cancer
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Genomics, phytochemicals, and oxidative stress
Helmholtz-Zentrum Dresden-Rossendorf
2023-2024
American University in Cairo
2021
British University in Egypt
2021
Yogurt is considered a nutritional, healthy dairy product that highly consumed worldwide produced via milk fermentation. The production process involves standard starter culture of lactic acid bacteria, such as Streptococcus thermophilus and Lactobacillus delbrueckii subsbulgaricus are essential for acidification consequently yogurt flavor generation. Different source combinations, supplementary probiotic cultures, additives nowadays used to enhance composition improve its consumer...
Abstract Doxorubicin (DOX) chemotherapy is associated with the release of inflammatory cytokines from macrophages. This has been suggested to be, in part, due DOX-mediated leakage endotoxins gut microflora, which activate Toll-like receptor 4 (TLR4) signaling macrophages, causing severe inflammation. However, direct function DOX on macrophages still unknown. In present study, we tested hypothesis that alone incapable stimulating response Then, compared anti-inflammatory effects curcumin...
Glioblastoma (GBM) is still an incurable tumor that associated with high recurrence rate and poor survival despite the current treatment regimes. With urgent need for novel therapeutic strategies, immunotherapies, especially chimeric antigen receptor (CAR)-expressing T cells, represent a promising approach specific effective targeting of GBM. However, CAR cells can be serious side effects. To overcome such limitation, we applied our switchable RevCAR system to target both epidermal growth...
Despite the success of chimeric antigen receptor (CAR) T-cells especially for treating hematological malignancies, critical drawbacks, such as “on-target, off-tumor” toxicities, need to be addressed improve safety in translating clinical application. This is true, when targeting tumor-associated antigens (TAAs) that are not exclusively expressed by solid tumors but also on hea9lthy tissues. To profile, we developed switchable adaptor CAR systems including RevCAR system. activated...
In recent studies, we have established the unique adapter chimeric antigen receptor (CAR) platform RevCAR which uses, as an extracellular CAR domain, a peptide epitope instead of antibody domain. adapters (termed target modules, RevTMs) are bispecific antibodies that enable reversible ON/OFF switch system, improving safety compared to conventional CARs. Here, describe for first time its use retargeting both T and NK-92 cells. addition, development preclinical validation novel RevTM targeting...